COVID-19 disease in children presenting to the pediatric emergency department: A multicenter study with 8886 cases from Turkey
dc.contributor.author | Duman M. | |
dc.contributor.author | Şık N. | |
dc.contributor.author | Tekşam Ö. | |
dc.contributor.author | Akça H. | |
dc.contributor.author | Kurt F. | |
dc.contributor.author | Çağlar A.A. | |
dc.contributor.author | Yıldız L.A. | |
dc.contributor.author | Taşar M.A. | |
dc.contributor.author | Fidancı İ. | |
dc.contributor.author | Yayla B.C.C. | |
dc.contributor.author | Yılmaz D. | |
dc.contributor.author | Güngör E. | |
dc.contributor.author | Demir Ş. | |
dc.contributor.author | Çokuğraş H. | |
dc.contributor.author | Cebeci S.O. | |
dc.contributor.author | Önal P. | |
dc.contributor.author | Saz E.U. | |
dc.contributor.author | Yurtseven A. | |
dc.contributor.author | Uysalol M. | |
dc.contributor.author | Yıldız R. | |
dc.contributor.author | Gümüş S. | |
dc.contributor.author | Bal A. | |
dc.contributor.author | Bayturan S.Ş. | |
dc.contributor.author | Zengin N. | |
dc.contributor.author | Atik S. | |
dc.contributor.author | Çiftdoğan D.Y. | |
dc.contributor.author | Berksoy E. | |
dc.contributor.author | Çiçek A. | |
dc.contributor.author | Şahin S. | |
dc.contributor.author | Kızıl M.C. | |
dc.contributor.author | Kara Y. | |
dc.contributor.author | Apa H. | |
dc.contributor.author | Ulusoy E. | |
dc.contributor.author | Kara A.A. | |
dc.contributor.author | Yesil E. | |
dc.contributor.author | Erdem M. | |
dc.contributor.author | Turan C. | |
dc.contributor.author | Arslanoglu S. | |
dc.contributor.author | Duyu M. | |
dc.contributor.author | Besli G.E. | |
dc.contributor.author | Arslan G. | |
dc.contributor.author | Oflu A.T. | |
dc.contributor.author | Çeleğen M. | |
dc.contributor.author | Buldu E. | |
dc.contributor.author | Pişkin İ.E. | |
dc.contributor.author | Kardeş H. | |
dc.contributor.author | Yılmaz H.L. | |
dc.contributor.author | Yıldızdaş D. | |
dc.contributor.author | Gökulu G. | |
dc.contributor.author | Çay P. | |
dc.contributor.author | Özer U. | |
dc.contributor.author | Güleryüz O.D. | |
dc.contributor.author | Çolak Ö. | |
dc.contributor.author | Güneysu S.T. | |
dc.date.accessioned | 2024-07-22T08:03:56Z | |
dc.date.available | 2024-07-22T08:03:56Z | |
dc.date.issued | 2022 | |
dc.description.abstract | Background: The aim was to evaluate the epidemiological, clinical, laboratory, and radiologic data of children with SARS-CoV-2 positivity by polymerase chain reaction (PCR) together with treatment strategies and clinical outcomes and to evaluate cases of multisystem inflammatory syndrome in children (MIS-C) in this population. Methods: This was a multicenter retrospective observational cohort study performed in the pediatric emergency departments of 19 tertiary hospitals. From March 11, 2020, to May 31, 2021, children who were diagnosed with confirmed nasopharyngeal/tracheal specimen SARS-CoV-2 PCR positivity or positivity for serum-specific antibodies against SARS-CoV-2 were included. Demographics, presence of chronic illness, symptoms, history of contact with SARS-CoV-2 PCR-positive individuals, laboratory and radiologic investigations, clinical severity, hospital admissions, and prognosis were recorded. Results: A total of 8886 cases were included. While 8799 (99.0%) cases resulted in a diagnosis of SARS-CoV-2 with PCR positivity, 87 (1.0%) patients were diagnosed with MIS-C. Among SARS-CoV-2 PCR-positive patients, 51.0% were male and 8.5% had chronic illnesses. The median age was 11.6 years (IQR: 5.0–15.4) and 737 (8.4%) patients were aged <1 year. Of the patients, 15.5% were asymptomatic. The most common symptoms were fever (48.5%) and cough (30.7%) for all age groups. There was a decrease in the rate of fever as age increased (p < 0.001); the most common age group for this symptom was <1 year with the rate of 69.6%. There was known contact with a SARS-CoV-2 PCR-positive individual in 67.3% of the cases, with household contacts in 71.3% of those cases. In terms of clinical severity, 83 (0.9%) patients were in the severe-critical group. There was hospital admission in 1269 (14.4%) cases, with 106 (1.2%) of those patients being admitted to the pediatric intensive care unit (PICU). Among patients with MIS-C, 60.9% were male and the median age was 6.4 years (IQR: 3.9–10.4). Twelve (13.7%) patients presented with shock. There was hospital admission in 89.7% of these cases, with 29.9% of the patients with MIS-C being admitted to the PICU. Conclusion: Most SARS-CoV-2 PCR-positive patients presented with a mild clinical course. Although rare, MIS-C emerges as a serious consequence with frequent PICU admission. Further understanding of the characteristics of COVID-19 disease could provide insights and guide the development of therapeutic strategies for target groups. © 2022 Elsevier Inc. | |
dc.identifier.DOI-ID | 10.1016/j.ajem.2022.06.015 | |
dc.identifier.issn | 07356757 | |
dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12494 | |
dc.language.iso | English | |
dc.publisher | W.B. Saunders | |
dc.rights | All Open Access; Green Open Access | |
dc.subject | Child | |
dc.subject | COVID-19 | |
dc.subject | Emergency Service, Hospital | |
dc.subject | Female | |
dc.subject | Fever | |
dc.subject | Humans | |
dc.subject | Male | |
dc.subject | Retrospective Studies | |
dc.subject | SARS-CoV-2 | |
dc.subject | Systemic Inflammatory Response Syndrome | |
dc.subject | antibiotic agent | |
dc.subject | favipiravir | |
dc.subject | hydroxychloroquine | |
dc.subject | hypertensive factor | |
dc.subject | immunoglobulin | |
dc.subject | immunomodulating agent | |
dc.subject | low molecular weight heparin | |
dc.subject | oseltamivir | |
dc.subject | SARS-CoV-2 antibody | |
dc.subject | steroid | |
dc.subject | adolescent | |
dc.subject | age distribution | |
dc.subject | Article | |
dc.subject | asymptomatic coronavirus disease 2019 | |
dc.subject | child | |
dc.subject | chronic disease | |
dc.subject | clinical examination | |
dc.subject | clinical feature | |
dc.subject | comorbidity | |
dc.subject | contact examination | |
dc.subject | controlled study | |
dc.subject | coronavirus disease 2019 | |
dc.subject | coughing | |
dc.subject | disease course | |
dc.subject | disease severity | |
dc.subject | emergency ward | |
dc.subject | extracorporeal oxygenation | |
dc.subject | female | |
dc.subject | fever | |
dc.subject | hospital admission | |
dc.subject | human | |
dc.subject | human cell | |
dc.subject | infant | |
dc.subject | laboratory test | |
dc.subject | major clinical study | |
dc.subject | male | |
dc.subject | medical history | |
dc.subject | morbidity | |
dc.subject | nasopharyngeal swab | |
dc.subject | observational study | |
dc.subject | pediatric intensive care unit | |
dc.subject | pediatric patient | |
dc.subject | pediatric ward | |
dc.subject | plasmapheresis | |
dc.subject | polymerase chain reaction | |
dc.subject | preschool child | |
dc.subject | prognosis | |
dc.subject | retrospective study | |
dc.subject | school child | |
dc.subject | sex difference | |
dc.subject | shock | |
dc.subject | systemic inflammatory response syndrome | |
dc.subject | tertiary care center | |
dc.subject | thorax radiography | |
dc.subject | treatment planning | |
dc.subject | Turkey (republic) | |
dc.subject | clinical trial | |
dc.subject | complication | |
dc.subject | diagnosis | |
dc.subject | epidemiology | |
dc.subject | fever | |
dc.subject | hospital emergency service | |
dc.subject | multicenter study | |
dc.title | COVID-19 disease in children presenting to the pediatric emergency department: A multicenter study with 8886 cases from Turkey | |
dc.type | Article |